Table 1.

Patient characteristics at the start of the run-in phase and patients with primary endpoints at the end of the 3-year trial phase

	All (SUP + IMM)	Supportive Care (SUP)	Supportive Care plus Immunosuppression (IMM)
	(N = 70)	(N = 32)	(N = 38)
Patient characteristics:
Female sex -%	17	13	21
Smoker -%	19	19	18
Age –yr	43.4 ± 13.6	48.2 ± 10.8	39.3 ± 14.5
Body-mass index	28.0 ± 5.0	29.0 ± 4.8	27.3 ± 5.1
Blood pressure- mmHg
Systolic	131 ± 14	135 ± 16	127 ± 12
Diastolic	82 ± 11	86 ± 11	79 ± 10
Serum creatinine -mg/dl	1.4 ± 0,5	1.5 ± 0.5	1.3 ± 0.5
eGFR-ml/min/1.73m2	67 ± 28	61 ± 25	73 ± 30
Creatinine clearance - ml/min	82 ± 34 (N = 60)	80 ± 30 (N = 28)	84 ± 37 (N = 32)
Daily urinary protein excretion - g/day	2.3 ± 1.3	2.4 ± 1.3	2.2 ± 1.3
Urinary protein-creatinine ratio - g/g	1.4 ± 0.8 (N = 60)	1.4 ± 0.8 (N = 28)	1.4 ± 0.8 (N = 32)
Cholesterol - mg/dl	210 ± 44 (N = 67)	208 ± 37 (N = 29)	211 ± 48(N = 38)
Primary endpoints:
Full clinical remissiona	8	2	6
eGFR-loss ≥15 ml/min	23	11	12
ESRDb	8	4	4

^aurinary protein-creatinine ratio < 0.2 g/g and an eGFR decrease of < 5 ml/min/1.73m²

^bend-stage renal disease